Samsung Bio-Logics, biosimilar projects a positive outlook - Dongbu Securities

[Korea goyounghun financial newspaper reporter] Dongbu Securities has given a positive outlook, saying about Miller piece of business during the Samsung Bio Bio Bio Logics for 6 days, Samsung aims to Recommendation Hold ₩ 162,000 shares.

Samsung said it has won a bio piece in the last three days (local time), rheumatoid arthritis and psoriasis, Humira indications related patent invalid litigation filed in British courts. Samsung has six sides and August 2016 Bar applied for permission from the EMA (European Medicines Agency) and the City of bio Humira treatment to Miller Korea sikyak SB5.

Dongbu Securities gujayong researchers "HUMIRA has a patent extension strategy of trying beubi Representative biopharmaceuticals posted a year $ 16 billion turnover 2016 is the launch of biosimilars is being delayed" and "substance patent Humira in October 2018 expired in Europe Ke beubi developer of Humira were scheduled to take the strategy to extend the patent period terminates add a duplicate patent continues, "he said.

Humira is a biosimilar being developed by Amgen and coherent Russ had lost the patent invalid patent lawsuits for recipe in November last year and September, respectively.

Nine researchers, "Humira seemed to bio-inevitable delays Miller naemeurosseo led to patent invalidity ruling on the piece Indications for Samsung Bio will be able to be ahead of the European time-to-market biosimilars," he said "patents still are manjiman was determined to be positive issues "in the share price.

He added, "Humira biosimilars have a high prescription demand when due to patent barriers bio Miller released a pipeline of the highest items expected value on success with a piece of Samsung Bio not easy," he said "substance patent aebeu rain held and If a patent that can be used as a formulation patent for defense purposes, including more than 70 all present and reflect it because it can be extended up to 2032 will continue to take the kids beubi strategy to stop the launch of biosimilars, "said analyzes.

Also it decided that "HUMIRA is positive for the first patent invalidity proceedings when the piece of bio Bio Samsung in terms of the prevailing Miller's business."



Financial Daily Economic News FNTIMES - unauthorized reproduction for commercial purposes in accordance with the Copyright Act, No copying, distribution,
Copyright ⓒ Korea's financial newspaper & FNTIMES.com